PARP1 and cancer: Promise for PARP inhibitors as a single agent also extends beyond BRCA cancers, as they have shown to be effective in sporadic tumours bearing no germline BRCA mutations, including high-grade serous ovarian cancers and triple-negative breast cancers [289] as well as in tumours with defects in other HR proteins.